

# Presentation of Carfilzomib Associated Thrombotic Microangiopathy

William Stolarek, Catherine Abern\*

1. University in Madison, Wisconsin, US
2. Department of Surgery, Emory university school of medicine, Atlanta, US

## Corresponding Author

Catherine Abern\*  
Department of Surgery, Emory university school of medicine,  
Atlanta, US,  
Email: catherinabern@yahoo.com

Received Date: Nov 20, 2021

Accepted Date: Nov 22, 2021

Published Date: Dec 19, 2021

## Abstract

Multiple Myeloma (MM) may be a lymph cell disorder characterised by abnormal proliferation of plasma cells leading to overrun of paraprotein. Proteasome inhibitors (PI) are a corner stone for the treatment of millimetre. TMA results in end-organ harm and infarct by microthrombi. TMA pathophysiology isn't well understood and has multiple etiologies. we tend to gift a case of PI-induced TMA, in conjunction with literature review of cases diagnosed from 2008-2018. distinctive to our case is that the onset of presentation, over twenty four months when initiating carfilzomib. Our case highlights the necessity for open-eyed observance and also the importance of clinical suspicion in patients in danger for TMA.

## Keywords

carfilzomib, thrombotic microangiopathy, proteasome inhibitors

## Introduction

Multiple Myeloma (MM) may be a lymph cell disorder characterised by abnormal proliferation of plasma cells leading to overrun of paraprotein. It represents concerning 100% of hematologic malignancies with associate incidence of twenty seven,000 each year [1]. Treatment typically includes therapy and in patients with superb response to therapy, more treatment with autologous organic process vegetative cell transplant (HSCT) [2].

Proteasome inhibitors (PI) are a corner stone for the treatment of millimetre [3,4,5] beginning with bortezomib a reversible PI that was approved in 2003, then the introduction of carfilzomib, associate irreversible and selective PI, that was approved in 2012. Carfilzomib was ab initio approved for treatment of refractory millimetre, however because of higher rates of response and improved survival, it has been progressively used each as a first-line medical aid and at relapse [6].

Well known aspect effects of PI embrace peripheral pathology, general and pulmonic high blood pressure, coronary failure, anemia, fatigue, thrombopenia, nausea, pyrexia, dyspnea, diarrhea, headache, and cough

[7]. Most grade three and four adverse effects (medically vital adverse events leading to hospitalization, morbidity or life threatening) area unit hematologic and embrace thrombopenia (23.4%), anemia (22.4%), and lymphopenia (18.1%) [8].

However, a probably fatal, underreported, and comparatively recently discovered adverse result is thrombotic microangiopathy (TMA) that involves epithelium cell injury and activation of the clotting cascade, inflicting thrombopenia and microangiopathic anaemia (MAHA). This cascade of events results in ultimate widespread microvascular occlusion and end-organ infarct. apparently whereas bortezomib has been gift for nearly a decade before carfilzomib, and has broader indications to be used, most of the reportable bortezomib-induced TMA cases were collected when carfilzomib use, seemingly because of heightened awareness of this serious complication. Hobeika et al. reportable the primary case of carfilzomib-induced urinary organ thrombotic microangiopathy on a urinary organ diagnostic assay in 2014 [9]. The reportable cases of this development occurred terribly shortly when initiation of treatment. Here, we tend to report a case of delayed onset carfilzomib-induced TMA occurring when receiving continuous medical aid for 2 years.

## Case Presentation

A 65-year-old-female with IgG-kappa-MM, Revised myeloma International Staging System (R-ISS) stage a pair of, diagnosed eight years past. She was ab initio treated with bortezomib associated adrenal cortical steroid (Vd) with superb response then an autologous organic process vegetative cell transplant. Post-transplant, she was treated with lenalidomide maintenance for thirteen months however eventually had illness progression. Second line treatment with bortezomib, cyclophosphamide and adrenal cortical steroid (VCD) was initiated, completed seven months of treatment. Her illness eventually progressed, and he or she was switched to carfilzomib, adrenal cortical steroid and pomalidomide (Kpd). The patient achieved complete remission when eight cycles of Kpd then continuing maintenance medical aid with carfilzomib monotherapy for one year till relapse. She was people with (Kpd), achieving superb partial response when four cycles. At patient request, her treatment was de-escalated to carfilzomib and adrenal cortical steroid (Kd) solely. The millimetre remained in restraint, the patient received a pair of cycles of Kd then bestowed with complaints of fatigue, lethargy, cough and symptom. Laboratory tests were exceptional for acute kidney disease, thrombopenia, and solution abnormalities. Creatinine was severely elevated at eleven mg/dL (baseline of zero.67 mg/dL), acid fifteen mg/dL, calcium 6.7 mg/dL, and phosphorus five.6 mg/dL. hemoprotein was at her baseline of eleven.5 gm/dL, RBC one.78%, traditional haematoidin, and peripheral blood smear was ordinary while not schistocytes. clotting parameter coagulation factor and activated clotting factor time were traditional.

She was suspected to possess neoplasm Lysis Syndrome (TLS) and allotted a Cairo-Bishop grade four, as creatinine rose over vi times the baseline, indicating severe TLS. The patient was hydrous smartly and given a dose of rasburicase. It represents organic chemistry markers of TLS at baseline and for the primary four days of her hospital keep.

The development of anemia and thrombopenia with laboratory proof of microangiopathic hemolysis raised the suspicion for carfilzomib

induced-TMA. ADAMTS13 activity level was forty eighth that dominated out thrombotic

thrombocytopenic purpura (TTP). alternative causes of TMA like disseminated intravascular clotting, mechanical valve, and uncontrolled high blood pressure were dominated out. It shows the initial and follow-up hematology parameters.

Hemodialysis and ancillary care were continuing although the patient's hospital course was sophisticated by bodily cavity and gi harm that was managed with a nucleon pump substance continuous drip. One week when hospitalization, the platelets and hemoprotein improved to close baseline and also the patient was eventually discharged. She sadly remained addicted to haemodialysis.

### Discussion

TMA encompasses a spectrum of 3 totally different conditions: haemolytic azotemic syndrome, atypical haemolytic azotemic syndrome (aHUS) and TTP; sharing the triad of Dhegiha, thrombopenia and kidney failure, however with totally different deed and presentation. best-known etiologies for TMA may be hereditary and acquired; hereditary etiologies embody ADAMTS13 deficiency and mutations touching the choice complement pathway. nonheritable causes of TMA embody infections, drug iatrogenic, and MM, that has been concerned as a reason for TMA significantly in cases of uncontrolled metric linear unit at the time of initial diagnosing. HSCT has additionally been related to Dhegiha and TMA, classified below a class known as transplant-associated thrombotic microangiopathy (TA-TMA) [10,11,12,13].

Drug iatrogenic TMA (DITMA) has been reportable with the utilization of various medications like quinines, clopidogrel, calcineurin inhibitors, cyclosporin, vascular epithelial tissue protein (VEGF) inhibitors, and chemotherapeutic agents like gemcitabine, antibiotic drug and proteasome inhibitors just like the subject in our case, PI [14,15,16]. There square measure many postulated mechanisms of PI iatrogenic TMA. One hypothesis is predicated on immune-mediated toxicity, as PIs could lead on to high levels of unhealthy cytokines (including IL-6 and TNF- $\alpha$ ), and build a microvascular surroundings giving the formation of drug-dependent antibodies [17].

Another mechanism is dose-mediated toxicity involving VEGF inhibition resulting in microvascular injury, significantly to capillary vessel capillaries. the same as the mechanism by that bevacizumab (anti-VEGF antibodies), pazopanib (VEGF 1-3 inhibitor) and sunitinib (VEGF amino acid enzyme inhibitor) will result in TMA-related urinary organ harm specifically via podocyte injury, inflicting albuminuria and high blood pressure [14,18,19].

Our literature review exploitation PubMed with the keywords: carfilzomib, bortezomib, proteasome inhibitors, TMA, thrombotic, microangiopathy, HUS, AHUS and TTP unconcealed reports nineteen cases of DITMA attributed to PI use between 2008-2018. In 2016, Yui et al [20] reviewed an extra eleven cases at six major establishments in United States of America and Europe that weren't enclosed as a result of the individual presentation and outcome for every case wasn't such that. Ixazomib, the foremost recent PI has additionally been coupled to DITMA, and three reportable cases square measure enclosed.

Similar to our patient, larger than ninetieth of the patients reviewed had acute urinary organ injury and over half the cases reportable complaints of fatigue and lethargy probably thanks to the second commonest presenting symptoms of looseness of the bowels and unconditioned reflex. Onset of DITMA when PI exposure varied wide within the represented cases starting from hours up to seventeen months, with a median of forty six days. Our case is somewhat distinctive thanks to the terribly late onset of presentation of TMA when receiving carfilzomib for twenty

three months. To the most effective of our information, presentation this so much out from initiation of treatment has not been reportable. Most of the reportable cases of PI iatrogenic TMA were managed with plasma exchange, transfusion, and chemical analysis. Twelve of nineteen cases achieved full recovery with numerous therapeutic measures; hemodialysis, plasmapheresis, discontinuing the PI, and accessory transfusion. 2 patients achieved full recovery with combined measures: one received apheresis, dialysis and eculizumab, and therefore the alternative achieved full recovery with apheresis and rituximab. With the unpredictable responses to varied therapeutic interventions, we tend to square measure unable to draw any conclusions relating to treatment effectiveness and more understanding of the pathophysiology of DITMA ought to be investigated.

Resolution of the DITMA when dialysis would possibly support the dose-dependent toxicity of the PI driving the DITMA, whereas its resolution when apheresis, eculizumab associated rituximab support the idea of an immune mediate mechanism driving DITMA.

Eculizumab may be a antibody against complement macromolecule C5 that inhibits the formation of C5a, a unhealthy protein. Complement targeted medical aid with eculizumab may be a well-established treatment for aHUS. 2 prospective studies revealed in 2013 all over that eculizumab is related to vital time-dependent improvement in nephritic perform in patients with atypical Hus [34]. Cytopenias inside 3-5 weeks. However, its use remains off-label and there remains no normal of take care of PI-induced TMA. The mechanism of eculizumab would possibly offer United States of America with higher understanding of the immunologic response in drug-induced TMA, however this remains a locality for more study.

Carfilzomib is apace changing into a corner-stone treatment in metric linear unit. Though TMA wasn't reportable with the initial trials [35], it's currently a recognized adverse result of carfilzomib. reportage adverse effects just in case series helps expand our information of the risks and edges of treatments. fast recognition of those symptoms and laboratory leads to relation to their temporal relationship to the initiation of PI also can save patients from potential fatal aspect effects, that can be reversible. Finally, our case highlights the necessity for alert observance and therefore the importance of clinical acumen and history taking in patients in danger for TMA, even when extended exposures to best-known contributive medicine.

### References

1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2015. *CA Cancer J Clin*, 2015. 65(1): p. 5-29.
2. Ludwig, H., et al., International Myeloma Working Group recommendations for global myeloma care. *Leukemia*, 2014. 28(5): p. 981-92.
3. Palumbo, A. and K. Anderson, Multiple myeloma. *N Engl J Med*, 2011. 364(11): p. 1046-60.
4. Adams, J. and M. Kauffman, Development of the proteasome inhibitor Velcade (Bortezomib). *Cancer Invest*, 2004. 22(2): p. 304-11.
5. Siegel, D.S., et al., A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood*, 2012. 120(14): p. 2817-25.
6. Dimopoulos, M.A., et al., Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised,

- phase 3, open-label, multicentre study. *Lancet Oncol*, 2016. 17(1): p. 27-38.
7. Chari, A. and D. Hajje, Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. *BMC Cancer*, 2014. 14: p. 915.
  8. Harvey, R.D., Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib. *Clin Pharmacol*, 2014. 6: p. 87-96.
  9. Hobeika, L., S.E. Self, and J.C. Velez, Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. *BMC Nephrol*, 2014. 15: p. 156.
  10. Noris, M. and G. Remuzzi, Atypical hemolytic-uremic syndrome. *N Engl J Med*, 2009. 361(17): p. 1676-87.
  11. Noris, M., et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol*, 2010. 5(10): p. 1844-59.
  12. Roy, V., et al., Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. *Bone Marrow Transplant*, 2001. 27(6): p. 641-6.
  13. Besbas, N., et al., A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. *Kidney Int*, 2006. 70(3): p. 423-31.
  14. Eremina, V., et al., VEGF inhibition and renal thrombotic microangiopathy. *N Engl J Med*, 2008. 358(11): p. 1129-36.
  15. Reese, J.A., et al., Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin. *Am J Hematol*, 2015. 90(5): p. 406-10.
  16. Al-Nouri, Z.L., et al., Drug-induced thrombotic microangiopathy: a systematic review of published reports. *Blood*, 2015. 125(4): p. 616-8.
  17. Moore, H. and K. Romeril, Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. *Intern Med J*, 2011. 41(4): p. 348-50.
  18. Eremina, V. and S.E. Quaggin, Biology of anti-angiogenic therapy-induced thrombotic microangiopathy. *Semin Nephrol*, 2010. 30(6): p. 582-90.
  19. Usui, J., et al., Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. *Hum Pathol*, 2014. 45(9): p. 1918-27.
  20. Yui, J.C., et al., Proteasome inhibitor associated thrombotic microangiopathy. *Am J Hematol*, 2016. 91(9): p. E348-52.
  21. Chan, K.L., et al., Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. *Leuk Lymphoma*, 2015. 56(7): p. 2185-6.
  22. Mehta, N., A. Saxena, and R. Niesvizky, Bortezomib-induced thrombotic thrombocytopenic purpura. *BMJ Case Rep*, 2012. 2012.
  23. Salmenniemi, U. and K. Remes, Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. *Hematol Rep*, 2012. 4(2): p. e13.
  24. Morita, R., et al., Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. *Int J Hematol*, 2008. 88(2): p. 248-250.
  25. Lodhi, A., et al., Thrombotic microangiopathy associated with proteasome inhibitors. *Clin Kidney J*, 2015. 8(5): p. 632-6.
  26. Sullivan, M.R., et al., Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. *J Clin Apher*, 2015. 30(5): p. 308-10.
  27. Qaqish, I., et al., Carfilzomib: A cause of drug associated thrombotic microangiopathy. *Transfus Apher Sci*, 2016. 54(3): p. 401-4.
  28. Gosain, R., et al., Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. *Clin Case Rep*, 2017. 5(12): p. 1926-1930.
  29. Chen, Y., et al., Thrombotic microangiopathy during carfilzomib use: case series in Singapore. *Blood Cancer Journal*, 2016. 6: p. e450.
  30. Atrash, S., et al., Fatal Thrombotic Microangiopathy Developing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM). *Blood*, 2012. 120(21): p. 5037-5037.
  31. Van Keer, J., et al., Renal Thrombotic Microangiopathy Associated with the Use of Bortezomib in a Patient with Multiple Myeloma. *Case Rep Hematol*, 2016. 2016: p. 6020691.
  32. Yui, J.C., A. Dispenzieri, and N. Leung, Ixazomib-induced thrombotic microangiopathy. *Am J Hematol*, 2017. 92(4): p. E53- e55.
  33. Atallah-Yunes, S.A. and M.H. Soe, Drug-Induced Thrombotic Microangiopathy due to Cumulative Toxicity of Ixazomib. *Case Rep Hematol*, 2018. 2018: p. 7063145.
  34. Legendre, C.M., et al., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. *N Engl J Med*, 2013. 368(23): p. 2169-81.
  35. Stewart, A.K., et al., Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*, 2015. 372(2): p. 142-52.